Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition

References

• van Hagen P, Hulshof MC, van Lanschot JJ, van Hagen P, van Lanschot JJB, Steyerberg EW, Henegouwen MIVB, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–14. doi:10.1056/NEJMoa1112088.
   PubMed Web of Science ®Google Scholar
• Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098. doi:10.1016/S1470-2045(15)00040-6.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, et al. Adjuvant Nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–1203. doi:10.1056/NEJMoa2032125.
   PubMed Web of Science ®Google Scholar
• van den Ende T, Clercq N, van Berge Henegouwen MI, van den Ende T, van Berge Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL, Schokker S, et al. Neoadjuvant chemoradiotherapy combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: a single arm phase ii feasibility trial (PERFECT). Clin Cancer Res. 2021;27(12):3351–3359. doi:10.1158/1078-0432.CCR-20-4443.
   PubMed Web of Science ®Google Scholar
• Nie R, Chen F, Provencio M, Wang Y, van den Ende T, van Laarhoven HWM, Yuan S, Pless M, Hayoz S, Zhou Z, et al. Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials. Eur J Cancer. 2023;186:211–221. doi:10.1016/j.ejca.2023.03.010.
   PubMed Web of Science ®Google Scholar
• Al-Kaabi A, van der Post RS, van der Werf LR, Wijnhoven BPL, Rosman C, Hulshof MCCM, van Laarhoven HWM, Verhoeven RHA, Siersema PD. Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study. Acta Oncol. 2021;60(4):497–504. doi:10.1080/0284186X.2020.1870246.
   PubMed Web of Science ®Google Scholar
• Goedegebuure RSA, Harrasser M, de Klerk LK, van Schooten TS, van Grieken NCT, Eken M, Grifhorst MS, Pocorni N, Jordanova ES, van Berge Henegouwen MI, et al. Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. Oncoimmunology. 2021;10(1):1954807. doi:10.1080/2162402X.2021.1954807.
   PubMed Web of Science ®Google Scholar
• Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang I-M, Fleener C. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? J ImmunoTher Cancer. 2019;7(1):325. doi:10.1186/s40425-019-0799-2.
   PubMed Web of Science ®Google Scholar
• Subrahmanyam PB, Dong Z, Gusenleitner D, Giobbie-Hurder A, Severgnini M, Zhou J, Manos M, Eastman LM, Maecker HT, Hodi FS, et al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J ImmunoTher Cancer. 2018;6(1):18. doi:10.1186/s40425-018-0328-8.
   PubMedGoogle Scholar
• Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114(19):4993–4998. doi:10.1073/pnas.1705327114.
   PubMed Web of Science ®Google Scholar
• Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–257. doi:10.1007/s00262-013-1508-5.
   PubMed Web of Science ®Google Scholar
• Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, Rasche L, Hartmann E, Dandekar T, Einsele H, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31(10):2181–2190. doi:10.1038/leu.2017.41.
   PubMed Web of Science ®Google Scholar
• Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, Xiong D, Liu Q, Tian Y, Lin H, et al. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 2022;185(22):4049–4066.e25. doi:10.1016/j.cell.2022.09.020.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li T, Lv J, Xiao L. Irradiated esophageal squamous cell carcinoma cells induced the increase of Treg by TGF-beta. JCO. 2021;39(15_suppl):e16092–e. doi:10.1200/JCO.2021.39.15_suppl.e16092.
   Google Scholar
• Steins A, Ebbing EA, Creemers A, Zalm AP, Jibodh RA, Waasdorp C, Meijer SL, Delden OM, Krishnadath KK, Hulshof MCCM, et al. Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma. Int J Cancer. 2019;145(10):2792–2803. doi:10.1002/ijc.32364.
   PubMed Web of Science ®Google Scholar
• Dongre A, Rashidian M, Reinhardt F. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77(15):3982–3989. doi:10.1158/0008-5472.CAN-16-3292.
   PubMed Web of Science ®Google Scholar
• Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M, et al. Tumor immune microenvironment during epithelial–mesenchymal transition. Clin Cancer Res. 2021;27(17):4669–4679. doi:10.1158/1078-0432.CCR-20-4459.
   PubMed Web of Science ®Google Scholar
• Scheffer HJ, Stam AGM, Geboers B, Vroomen LGPH, Ruarus A, de Bruijn B, van den Tol MP, Kazemier G, Meijerink MR, de Gruijl TD, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. Oncoimmunology. 2019;8(11):1652532. doi:10.1080/2162402X.2019.1652532.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Deshmukh AP, den Hollander P, Addanki S, Kuburich NA, Kudaravalli S, Joseph R, Chang JT, Soundararajan R, Mani SA, et al. Emtome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. Br J Cancer. 2021;124(1):259–269. doi:10.1038/s41416-020-01178-9.
   PubMed Web of Science ®Google Scholar
• Gibbons DL, Creighton CJ. Pan-cancer survey of epithelial-mesenchymal transition markers across the cancer genome atlas. Dev Dyn. 2018;247(3):555–564. doi:10.1002/dvdy.24485.
   PubMed Web of Science ®Google Scholar
• De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C, Bonnal RP, Provasi E, Sarnicola M, Panzeri I, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity. 2016;45(5):1135–1147. doi:10.1016/j.immuni.2016.10.021.
   PubMed Web of Science ®Google Scholar
• Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862. doi:10.1371/journal.pone.0051862.
   PubMed Web of Science ®Google Scholar
• Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Sig Transduct Target Ther. 2021;6(1):362. doi:10.1038/s41392-021-00670-9.
   PubMed Web of Science ®Google Scholar
• Liang Y, Wang W, Zhu X, Yu M, Zhou C. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer. Sci Rep. 2022;12(1):9619. doi:10.1038/s41598-022-13855-1.
   PubMed Web of Science ®Google Scholar
• Schiott A, Lindstedt M, Johansson-Lindbom B, Roggen E, Borrebaeck CAK. CD27- CD4+ memory T cells define a differentiated memory population at both the functional and transcriptional levels. Immunology. 2004;113(3):363–370. doi:10.1111/j.1365-2567.2004.01974.x.
   PubMed Web of Science ®Google Scholar
• Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat Immunol. 2011;12(6):467–471. doi:10.1038/ni.2038.
   PubMed Web of Science ®Google Scholar
• Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):101. doi:10.1186/s13045-017-0471-6.
   PubMed Web of Science ®Google Scholar
• Petty AJ, Li A, Wang X. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest. 2019;129(12):5151–5162. doi:10.1172/JCI128644.
   PubMed Web of Science ®Google Scholar
• Ren J, Hou Y, Wang T. Roles of estrogens on myeloid-derived suppressor cells in cancer and autoimmune diseases. Cell Mol Immunol. 2018;15(7):724–726. doi:10.1038/cmi.2017.129.
   PubMed Web of Science ®Google Scholar
• Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S, Hobor S, Hock AK, Walton JB, Morton JP, Gronroos E, et al. Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Rep. 2020;30(2):481–96 e6. doi:10.1016/j.celrep.2019.12.028.
   PubMed Web of Science ®Google Scholar
• Huang CT, Chang MC, Chen YL. Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation. Cancer Lett. 2015;359(1):117–126. doi:10.1016/j.canlet.2015.01.007.
   PubMed Web of Science ®Google Scholar
• Andersen LB, Norgaard M, Rasmussen M, Fredsøe J, Borre M, Ulhøi BP, Sørensen KD. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol. 2021;255(2):155–165. doi:10.1002/path.5757.
   PubMed Web of Science ®Google Scholar
• Deng L, Zhang H, Luan Y. Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res. 2010;16(16):4105–4112. doi:10.1158/1078-0432.CCR-10-1073.
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C, et al. The expression of the regulatory T cell–specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11(23):8326–8331. doi:10.1158/1078-0432.CCR-05-1244.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity. Cell. 2019;177(3):556–71 e16. doi:10.1016/j.cell.2019.02.005.
   PubMed Web of Science ®Google Scholar
• Feng AL, Zhu JK, Sun JT, Yang M-X, Neckenig MR, Wang X-W, Shao Q-Q, Song B-F, Yang Q-F, Kong B-H, et al. CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis. Clin Exp Immunol. 2011;164(1):57–65. doi:10.1111/j.1365-2249.2011.04321.x.
   PubMed Web of Science ®Google Scholar
• Eljaszewicz A, Jankowski M, Gackowska L, Helmin-Basa A, Wiese M, Kubiszewska I, Kaszewski W, Michalkiewicz J, Zegarski W. Clinical immunologyGastric cancer increase the percentage of intermediate (CD14++CD16+) and nonclassical (CD14+CD16+) monocytes. Cent Eur J Immunol. 2012;4(4):355–361. doi:10.5114/ceji.2012.32725.
   Google Scholar
• Subimerb C, Pinlaor S, Lulitanond V, Khuntikeo N, Okada S, McGrath MS, Wongkham S. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol. 2010;161(3):471–479. doi:10.1111/j.1365-2249.2010.04200.x.
   PubMed Web of Science ®Google Scholar
• Sponaas AM, Moen SH, Liabakk NB, Feyzi E, Holien T, Kvam S, Grøseth LAG, Størdal B, Buene G, Espevik T, et al. The proportion of CD16 + CD14 dim monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma. Immun Inflamm Dis. 2015;3(2):94–102. doi:10.1002/iid3.53.
   PubMedGoogle Scholar
• Prat M, Le Naour A, Coulson K, Lemée F, Leray H, Jacquemin G, Rahabi MC, Lemaitre L, Authier H, Ferron G, et al. Circulating CD14 high CD16 low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. J ImmunoTher Cancer. 2020;8(1):e000472. doi:10.1136/jitc-2019-000472.
   PubMed Web of Science ®Google Scholar
• Salvador-Coloma C, Santaballa A, Sanmartin E, Calvo D, García A, Hervás D, Cordón L, Quintas G, Ripoll F, Panadero J, et al. Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Cancer. 2020;139:119–134. doi:10.1016/j.ejca.2020.08.020.
   PubMed Web of Science ®Google Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28. doi:10.1016/S1470-2045(12)70582-X.
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2):539–549. doi:10.1158/0008-5472.CAN-12-2325.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Suzuki S, Takahara T, Ono S, Goto M, Miyabe S, Sugita Y, Ogawa T, Ito H, Satou A, et al. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma. Cancer Sci. 2021;112(10):4037–4049. doi:10.1111/cas.15081.
   PubMed Web of Science ®Google Scholar
• Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356–371. doi:10.1038/s41571-019-0175-7.
   PubMed Web of Science ®Google Scholar
• Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol. 2009;21(5):257–264. doi:10.1016/j.smim.2009.05.011.
   PubMed Web of Science ®Google Scholar
• Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 2012;120(15):3030–3038. doi:10.1182/blood-2012-05-427799.
   PubMed Web of Science ®Google Scholar
• Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA. The complex role of tumor-infiltrating macrophages. Nat Immunol. 2022;23(8):1148–1156. doi:10.1038/s41590-022-01267-2.
   PubMed Web of Science ®Google Scholar
• Kong X, Zhu M, Wang Z, Xu Z, Shao J. Characteristics and clinical significance of CD163+/CD206+M2 mono-macrophage in the bladder cancer microenvironment. Turk J Biol. 2021;45(5):624–632. doi:10.3906/biy-2104-17.
   PubMed Web of Science ®Google Scholar
• Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. Clin Transl Med. 2020;10(1):199–223. doi:10.1002/ctm2.24.
   PubMed Web of Science ®Google Scholar
• Tan JT, Zhong JH, Yang Y, Mao N-Q, Liu D-S, Huang D-M, Zhao Y-X, Zuo C-T. Comparison of postoperative immune function in patients with thoracic esophageal cancer after video-assisted thoracoscopic surgery or conventional open esophagectomy. Int J Surg. 2016;30:155–160. doi:10.1016/j.ijsu.2016.04.052.
   PubMed Web of Science ®Google Scholar
• Donlon NE, Davern M, Sheppard AD, O’Connell F, Dunne MR, Hayes C, Mylod E, Ramjit S, Temperley H, Mac Lean M, et al. The impact of esophageal oncological surgery on perioperative immune function; implications for adjuvant immune checkpoint inhibition. Front Immunol. 2022;13:823225. doi:10.3389/fimmu.2022.823225.
   PubMed Web of Science ®Google Scholar